{"id":18342,"date":"2015-12-30T11:38:45","date_gmt":"2015-12-30T10:38:45","guid":{"rendered":"http:\/\/blog.cofb.cat\/?p=18342"},"modified":"2015-12-30T11:38:45","modified_gmt":"2015-12-30T10:38:45","slug":"seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/es\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/","title":{"rendered":"Seguimiento del paciente diab\u00e9tico tipo II en la farmacia comunitaria"},"content":{"rendered":"<figure id=\"attachment_18345\" aria-describedby=\"caption-attachment-18345\" style=\"width: 298px\" class=\"wp-caption alignleft\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/12\/curs-pacient-diabetic-tipusII-1.jpg\"><img fetchpriority=\"high\" decoding=\"async\" class=\"wp-image-18345\" alt=\"curs-pacient-diabetic-tipusII (1)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/12\/curs-pacient-diabetic-tipusII-1.jpg\" width=\"298\" height=\"199\" \/><\/a><figcaption id=\"caption-attachment-18345\" class=\"wp-caption-text\">El doctor Pere Trav\u00e9 fue uno de los docentes del curso que acogi\u00f3 el COFB<\/figcaption><\/figure>\n<p>Los datos de prevalencia de la diabetes en todo el mundo son muy elevados. La edad, la obesidad, la presencia de historia familiar, las etnias, el sedentarismo, un nivel socioecon\u00f3mico bajo, la tolerancia a la glucosa alterada, la hipertensi\u00f3n arterial y la hiperlipemia son factores de riesgo que se asocian al desarrollo de la diabetes mellitus tipo 2 (DM2). <b>Establecer un buen control y seguimiento del paciente diab\u00e9tico mejora la adherencia al tratamiento, el grado de cumplimiento de la terapia diet\u00e9tica o la resoluci\u00f3n de los problemas que presenta en general el programa terap\u00e9utico<\/b>, al tiempo que facilita el control glucometab\u00f3lico, la reducci\u00f3n de la aparici\u00f3n de manifestaciones agudas y cr\u00f3nicas o aten\u00faa el impacto si ya han aparecido.<\/p>\n<p>Con el objetivo de formar y responsabilizar al farmac\u00e9utico en las tareas de prevenci\u00f3n, seguimiento farmacoterap\u00e9utico y control del paciente con esta enfermedad, el COFB acogi\u00f3 en noviembre el <strong>curso \u201cSeguimiento del paciente diab\u00e9tico tipo II\u201d<\/strong>. La formaci\u00f3n permiti\u00f3 establecer mecanismos de coordinaci\u00f3n con los equipos de atenci\u00f3n primaria; tambi\u00e9n dar a conocer las estrategias diet\u00e9ticas que pueden ayudar al paciente diab\u00e9tico a conseguir cambios en los h\u00e1bitos de alimentaci\u00f3n y actividad f\u00edsica que logren mejorar el control metab\u00f3lico, permitiendo que los farmac\u00e9uticos asistentes implementen estos servicios profesionales en la farmacia comunitaria. \u201cEstos servicios se orientan a la <b>prevenci\u00f3n de la enfermedad, la detecci\u00f3n de posibles pacientes de riesgo, la identificaci\u00f3n de pacientes diab\u00e9ticos mal controlados y el seguimiento farmacoterap\u00e9utico personalizado <\/b>del paciente diab\u00e9tico para facilitarle la adherencia y la seguridad del tratamiento farmacol\u00f3gico para evitar la aparici\u00f3n de efectos adversos indeseables\u201d explica <b>Pere Trav\u00e9<\/b>, doctor en farmacia y diplomado en el Instituto Pasteur de Paris, especialista en an\u00e1lisis cl\u00ednicos y bioqu\u00edmico cl\u00ednico, y uno de los docentes del curso.<\/p>\n<p>La formaci\u00f3n se llev\u00f3 a cabo mediante el abordaje de h\u00e1bitos higi\u00e9nico-diet\u00e9ticos que implican la implementaci\u00f3n de programas de p\u00e9rdida de peso y planes de ejercicio f\u00edsico que conduzcan a disminuir el riesgo de la enfermedad. \u201cSin embargo, se han desarrollado herramientas para la detecci\u00f3n precoz de la enfermedad, dado que <strong>se estima que por cada paciente diab\u00e9tico conocido, existe otro que lo desconoce<\/strong> y que su frecuencia aumenta significativamente con la edad, el exceso de peso y vida sedentaria\u201d explica Trav\u00e9, y para abordar el problema \u201cse ha destinado un tiempo de aprendizaje para promover el cribado en la poblaci\u00f3n susceptible de riesgo , seg\u00fan las recomendaciones del Ministerio de Sanidad\u201d.<\/p>\n<figure id=\"attachment_18347\" aria-describedby=\"caption-attachment-18347\" style=\"width: 572px\" class=\"wp-caption aligncenter\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/12\/curs-pacient-diabetic-tipusII-3.jpg\"><img decoding=\"async\" class=\"wp-image-18347\" alt=\"curs-pacient-diabetic-tipusII (3)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/12\/curs-pacient-diabetic-tipusII-3.jpg\" width=\"572\" height=\"349\" \/><\/a><figcaption id=\"caption-attachment-18347\" class=\"wp-caption-text\">Asistentes al curso de seguimiento del paciente diab\u00e9tico tipo II<\/figcaption><\/figure>\n<p>Por otra parte, y <strong>dado que el paciente diab\u00e9tico presenta un alto riesgo cardiovascular y que \u00e9ste puede ser identificado en la farmacia, se llevaron a cabo ejercicios en el aula de c\u00e1lculo del riesgo coronario<\/strong> seg\u00fan las <a href=\"http:\/\/www.regicor.org\/presentacio\/que-es\/framingham-regicor.html\" target=\"_blank\" rel=\"noopener\">tablas Regicor<\/a>, adaptadas a la poblaci\u00f3n catalana y con las <a href=\"http:\/\/www.escardio.org\/Guidelines-&amp;-Education\/Practice-tools\/CVD-prevention-toolbox\/SCORE-Risk-Charts\" target=\"_blank\" rel=\"noopener\">tablas Score de riesgo cardiovascular<\/a>, adaptadas a la poblaci\u00f3n europea, para que los farmac\u00e9uticos asistentes adquirieran las competencias necesarias para llevar a cabo este servicio.<\/p>\n<p>Dada la importancia de llevar un control desde la farmacia de los pacientes que padecen esta enfermedad -la diabetes es una de las principales causas de insuficiencia renal y los pacientes diab\u00e9ticos requerir\u00edan un control farmac\u00e9utico de sus medicamentos a la vez que tambi\u00e9n es necesario tener presente las posibles complicaciones que esta enfermedad puede causarlo, se consider\u00f3 de inter\u00e9s profundizar en los sistemas para la mejora del uso efectivo y seguro de los medicamentos que utilizan: \u201cConcretamente, en el curso se trabaj\u00f3 el m\u00e9todo de determinaci\u00f3n de la funci\u00f3n renal mediante el filtrado glomerular, accediendo a la <a href=\"http:\/\/www.senefro.org\/modules.php?name=calcfg\" target=\"_blank\" rel=\"noopener\">p\u00e1gina web de la Sociedad Espa\u00f1ola de Nefrolog\u00eda (SEN)<\/a> para entrenar el significado y uso de las f\u00f3rmulas, as\u00ed como la categorizaci\u00f3n de la enfermedad renal\u201d matiza Trav\u00e9. El <b>seguimiento farmacoterap\u00e9utico de los pacientes diab\u00e9ticos en la farmacia es un servicio farmac\u00e9utico de elevada importancia, <\/b>dado que estos pacientes necesitan un <b>control peri\u00f3dico de su medicaci\u00f3n<\/b> para garantizar que se utilicen de forma segura en funci\u00f3n de la p\u00e9rdida de la funcionalidad renal.<\/p>\n<p>Aparte del doctor Trav\u00e9, el equipo docente estuvo formado por <strong>Merc\u00e8 Mercad\u00e9<\/strong>, farmac\u00e9utica comunitaria y miembro del grupo de trabajo de atenci\u00f3n farmac\u00e9utica del COFB, y <strong>Gemma Trib\u00f3<\/strong>, farmac\u00e9utica comunitaria, diploma en Alimentaci\u00f3n y nutrici\u00f3n comunitaria de la Escuela Nacional de Sanidad, profesora asociada de estancias de pr\u00e1cticas tuteladas de la Facultad de Farmacia y profesora del master oficial de farmacia asistencial de la UB. La coordinaci\u00f3n corri\u00f3 a cargo de <strong>Merc\u00e8 Barau<\/strong>, vocal de la Junta de Gobierno del Colegio.<\/p>\n<p><strong>Quiz\u00e1s tambi\u00e9n te interesa:<\/strong><\/p>\n<ul>\n<li><a href=\"http:\/\/blog.cofb.cat\/les-farmacies-de-barcelona-realitzaran-proves-per-identificar-factors-de-risc-cardiovascular-a-10-anys\/\">Las farmacias de Barcelona realizar\u00e1n pruebas para identificar factores de riesgo cardiovascular a 10 a\u00f1os<\/a>\u00a0(Blog)<\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/14-de-novembre-dia-mundial-de-la-diabetis\/\">14 de noviembre: D\u00eda Mundial de la Diabetes<\/a>\u00a0(Blog)<\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/la-farmacia-comunitaria-aprofundeix-coneixements-en-el-pla-de-salut\/\">La farmacia comunitaria profundiza conocimientos en el Plan de Salud<\/a>\u00a0(Blog)<\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/diabetis-com-es-poden-prevenir-o-reduir-les-complicacions\/\">Diabetes: \u00bfc\u00f3mo prevenir o reducir las complicaciones? (v\u00eddeo)<\/a>\u00a0(Blog)<\/li>\n<\/ul>\n<p align=\"right\"><b>Con la colaboraci\u00f3n de:<\/b><\/p>\n<p align=\"right\"><b><a href=\"http:\/\/www.roche.es\/\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" class=\"alignright size-full wp-image-13052\" alt=\"roche\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/04\/roche.jpg\" width=\"120\" height=\"62\" \/><\/a><\/b><\/p>\n<p align=\"right\"><em>\u00a0<\/em><em>\u00a0\u00a0<\/em><i><em><br \/>\n<\/em><\/i><\/p>\n<p align=\"right\"><em><a href=\"http:\/\/www.rapidcontrol.es\/\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" class=\"alignright  wp-image-18365\" alt=\"rapid control\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/12\/rapid-control.jpg\" width=\"190\" height=\"103\" \/><\/a>\u00a0\u00a0<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>Los datos de prevalencia de la diabetes en todo el mundo son muy elevados. La edad, la obesidad, la presencia de historia familiar, las etnias, el sedentarismo, un nivel socioecon\u00f3mico bajo, la tolerancia a la glucosa alterada, la hipertensi\u00f3n arterial y la hiperlipemia son factores de riesgo que se asocian al desarrollo de la [\u2026]<\/p>","protected":false},"author":1,"featured_media":18346,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[57],"tags":[197,2298,113,69],"class_list":["post-18342","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mon-collegial","tag-diabetis","tag-dm2","tag-farmacia-assistencial","tag-farmacia-comunitaria"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Seguiment del pacient diab\u00e8tic tipus II a la farm\u00e0cia comunit\u00e0ria - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Seguiment del pacient diab\u00e8tic tipus II a la farm\u00e0cia comunit\u00e0ria - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Les dades de prevalen\u00e7a de la diabetis a tot el m\u00f3n s\u00f3n molt elevades. L\u2018edat, l\u2018obesitat, la pres\u00e8ncia d\u2018hist\u00f2ria familiar, les \u00e8tnies, el sedentarisme, un nivell socioecon\u00f2mic baix, la toler\u00e0ncia a la glucosa alterada, la hipertensi\u00f3 arterial i la hiperlip\u00e8mia s\u00f3n factors de risc que s\u2018associen al desenvolupament de la [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-12-30T10:38:45+00:00\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Seguiment del pacient diab\u00e8tic tipus II a la farm\u00e0cia comunit\u00e0ria\",\"datePublished\":\"2015-12-30T10:38:45+00:00\",\"dateModified\":\"2015-12-30T10:38:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/\"},\"wordCount\":935,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"diabetis\",\"DM2\",\"farm\u00e0cia assistencial\",\"farm\u00e0cia comunit\u00e0ria\"],\"articleSection\":[\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/\",\"name\":\"Seguiment del pacient diab\u00e8tic tipus II a la farm\u00e0cia comunit\u00e0ria - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2015-12-30T10:38:45+00:00\",\"dateModified\":\"2015-12-30T10:38:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Seguiment del pacient diab\u00e8tic tipus II a la farm\u00e0cia comunit\u00e0ria\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Seguiment del pacient diab\u00e8tic tipus II a la farm\u00e0cia comunit\u00e0ria - Col\u00b7legi de Farmac\u00e8utics de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/","og_locale":"es_ES","og_type":"article","og_title":"Seguiment del pacient diab\u00e8tic tipus II a la farm\u00e0cia comunit\u00e0ria - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"Les dades de prevalen\u00e7a de la diabetis a tot el m\u00f3n s\u00f3n molt elevades. L\u2018edat, l\u2018obesitat, la pres\u00e8ncia d\u2018hist\u00f2ria familiar, les \u00e8tnies, el sedentarisme, un nivell socioecon\u00f2mic baix, la toler\u00e0ncia a la glucosa alterada, la hipertensi\u00f3 arterial i la hiperlip\u00e8mia s\u00f3n factors de risc que s\u2018associen al desenvolupament de la [&hellip;]","og_url":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2015-12-30T10:38:45+00:00","author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrito por":"wpAdminCofbOrg","Tiempo de lectura":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Seguiment del pacient diab\u00e8tic tipus II a la farm\u00e0cia comunit\u00e0ria","datePublished":"2015-12-30T10:38:45+00:00","dateModified":"2015-12-30T10:38:45+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/"},"wordCount":935,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#primaryimage"},"thumbnailUrl":"","keywords":["diabetis","DM2","farm\u00e0cia assistencial","farm\u00e0cia comunit\u00e0ria"],"articleSection":["M\u00f3n col\u00b7legial"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/","url":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/","name":"Seguiment del pacient diab\u00e8tic tipus II a la farm\u00e0cia comunit\u00e0ria - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#primaryimage"},"thumbnailUrl":"","datePublished":"2015-12-30T10:38:45+00:00","dateModified":"2015-12-30T10:38:45+00:00","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2015\/12\/30\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Seguiment del pacient diab\u00e8tic tipus II a la farm\u00e0cia comunit\u00e0ria"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"Les dades de prevalen\u00e7a de la diabetis a tot el m\u00f3n s\u00f3n molt elevades. L\u2018edat, l\u2018obesitat, la pres\u00e8ncia d\u2018hist\u00f2ria familiar, les \u00e8tnies, el sedentarisme, un nivell socioecon\u00f2mic baix, la toler\u00e0ncia a la glucosa alterada, la hipertensi\u00f3 arterial i la hiperlip\u00e8mia s\u00f3n factors de risc que s\u2018associen al desenvolupament de la [&hellip;]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/18342","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/comments?post=18342"}],"version-history":[{"count":0,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/18342\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/media?parent=18342"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/categories?post=18342"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/tags?post=18342"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}